Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates. Issue 2 (25th March 2022)

• Record Type: Journal Article
• Authors: Huang, Kun; Zhen, Yingzi; Li, Gang; Wu, Xinyi; Chen, Zhenping; Wu, Runhui
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 6:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-25
• Subjects: bleeding -- child -- factor VIII -- hemophilia -- pharmacokinetics; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12686
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: Background: BAY81‐8973 (Kovaltry; Bayer, Berkeley, CA, USA) was reported with enhanced pharmacokinetic (PK) profiles compared with some other standard half‐life (SHL) factor VIII (FVIII) concentrates. Limited head‐to‐head comparative studies were conducted in a real‐world setting. Objective: To make head‐to‐head comparisons of PK and clinical outcomes between Kovaltry and three other SHL FVIII concentrates. Methods: Forty‐seven boys with severe hemophilia A were enrolled and divided into three groups according to their previously used FVIII concentrates (Kogenate FS, N = 22; Advate, N = 14; GreenMono, N = 11). Two separate PK tests were conducted in each participant with a five‐point assay during the study period from 6 months before switching to 6 months after switching. FVIII levels were detected by one‐stage assay, and PK profiles were calculated by noncompartmental assay. Annualized bleeding rates were collected through participant' bleed logs. Results: Longer half‐life time (Kogenate FS group: 14.4 vs 11.9 hours, P < .0001; Advate group: 13.4 vs 9.7 hours, P < .0001; GreenMono group: 15.1 vs 10.7 hours, P < .001]) and lower clearance (Kogenate FS group: 3.3 vs 3.9 mL/kg/h, P < .01; Advate group: 3.7 vs 5.9 mL/kg/h, P < .01; GreenMono group: 3.0 vs 5.1 mL/kg/h, P < .01) were observed with Kovaltry. In addition, longer mean residential time ( P < .01) and higher area under the curve ( P < .01) were demonstrated. No statistical difference was found in in vivo recovery between Kovaltry and the other FVIII products. Participants who switched to Kovaltry from three other FVIII concentrates with the same dosing regimens obtained higher trough FVIII levels and better protection with reduced annualized bleeding rates. Conclusion: Compared with Kogenate FS, Advate, and GreenMono, Kovaltry showed enhanced PK profiles, which contributed to reduced bleeding rates.